AMA Clinical Examples in Radiology - 2024 Issue 1 (Winter)
Nuclear Medicine Lutetium (Lu) 177 Vipivotide Tetraxetan (Lu-177 PSMA-617) Therapy
Winter 2024 pages 4-12 CLINICAL EXAMPLE 1: Nuclear Medicine Lutetium (Lu) 177 Vipivotide Tetraxetan (Lu-177 PSMA-617) Therapy CLINICAL INDICATION A 72-year-old male with a history of metastatic castration-resistant prostate cancer (mCRPC), with a recent prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) scan showing diffuse, intensely PSMA-avid osseous metastases. PROCEDURE Lutetium 177 (Lu-177) vipivotide tetraxetan (PSMA-617) nuclear medicine prostate cancer therapy TECHNIQUE Intravenous infusion of 205 mCi of Lu-177 PSMA-617 for the treatment of metastatic prostate cancer without any immediate complications FINDINGS Pre-Procedure Pre-therapy laboratory values were reviewed and were within an acceptable range for treatment. The patient's PSMA...
Subscribe or sign in to view the full article.
Article Overview
This article reviews a nuclear medicine therapy case involving lutetium Lu-177 vipivotide tetraxetan for metastatic prostate cancer and explains the coding context around the service. It is aimed at coding professionals, radiology/nuclear medicine staff, and anyone needing to understand the relevant CPT, HCPCS Level II, and ICD-10-CM references discussed in the example. The article also references professional guidance sources and general documentation and reporting considerations tied to the therapy.
Why This Topic Matters
It helps readers recognize the coding framework used for a specialized oncology therapy and understand which code sets are implicated in the reported case.
Article Sections
-
Clinical Example 1
A single nuclear medicine therapy case is presented with clinical context, procedure documentation, and pre- and post-treatment discussion. The example centers on a metastatic prostate cancer scenario and the related reporting environment.
-
How to Code
This section identifies the coding framework associated with the reported service and the related diagnosis coding context. It also notes the separate reporting of the therapeutic radiopharmaceutical product.
-
Discussion
Background information is provided on the therapy type, its clinical setting, and the supporting coding guidance cited by the article. The discussion also references general reporting considerations and source materials.
What You Will Learn
- The clinical setting for a nuclear medicine prostate cancer therapy example
- How the article frames the associated coding categories
- Which major code sets are referenced in the case discussion
- What supporting guidance sources are cited by the article
- The general documentation and follow-up context surrounding the therapy
Who Should Read This
- Medical coders
- Radiology coders
- Nuclear medicine staff
- Oncology documentation teams
- Compliance and reimbursement professionals
Codes Discussed
Subscribe or sign in to view the full article.


Quick, Current, Complete - www.findacode.com